Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 15/20 | 0.38 |
| ▸ | RARA | P10276 | 5/20 | 0.38 |
| ▸ | RXRG | P48443 | 3/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.38 |
| ▸ | RARB | P10826 | 6/20 | 0.36 |
| ▸ | RXRB | P28702 | 2/20 | 0.36 |
| ▸ | RARG | P13631 | 6/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194526 | 0.73 | MAOB (0.46) | MAOAMAOBRXRARARARXRG | |
| SCHEMBL8773385 | 0.70 | RAB9A (0.55) | MAOAMAOBPBRM1 | |
| SCHEMBL8308676 | 0.70 | ALDH1A1 (0.54) | MAOB | |
| SCHEMBL8309629 | 0.68 | RARA (0.36) | RXRARARARXRGNR4A2RARB | |
| SCHEMBL8809982 | 0.67 | HIF1A (0.41) | RXRARARARXRGRARBRXRB | |
| SCHEMBL6337769 | 0.67 | RXRA (0.32) | RXRARARARXRGNR4A2RARB | |
| SCHEMBL15665861 | 0.65 | RXRA (0.41) | RXRARARARXRGRARBRXRB | |
| SCHEMBL8043472 | 0.65 | MAOB (0.61) | MAOAMAOB | |
| SCHEMBL3061673 | 0.65 | RXRA (0.39) | RXRARARARXRGRARBRXRB | |
| SCHEMBL8810467 | 0.63 | CDC25B (0.41) | RXRARARARXRGRARBRXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | CANAN-KOCH STACIE (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1336600-A2 | Dimer-selective RXR modulators and methods for their use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6545049-B1 | E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof | LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-08 | — | — | US | disclosed |
| EP-0933351-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0933350-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0873295-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
| EP-0800504-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1997012853-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-04-10 | — | — | WO | disclosed |
| WO-1996020914-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | RXRG, RXRB, RXRA | MAOA 4479/4885MAOB 4382/4885RXRA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.